These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 36945037)

  • 1. Serum immuno-oncology markers carry independent prognostic information in patients with newly diagnosed metastatic breast cancer, from a prospective observational study.
    Gunnarsdottir FB; Bendahl PO; Johansson A; Benfeitas R; Rydén L; Bergenfelz C; Larsson AM
    Breast Cancer Res; 2023 Mar; 25(1):29. PubMed ID: 36945037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
    Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
    Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression in metastatic breast cancer-patterns in primary tumors and metastatic tissue with prognostic potential.
    Tutzauer J; Larsson AM; Aaltonen K; Bergenfelz C; Bendahl PO; Rydén L
    Front Mol Biosci; 2023; 10():1343979. PubMed ID: 38449790
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study.
    Bidard FC; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Cottu P; Beuzeboc P; Rolland E; Mathiot C; Pierga JY
    Breast Cancer Res; 2012 Feb; 14(1):R29. PubMed ID: 22330883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
    Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
    BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value.
    Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE
    Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
    Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
    J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Pantel K; Rack B; Janni W; Fasching PA; Aktas B; Kasimir-Bauer S; Hartkopf A; Solomayer EF; Fehm T; Müller V
    Breast Cancer Res Treat; 2018 Nov; 172(1):93-104. PubMed ID: 30003393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.
    Cristofanilli M; Hayes DF; Budd GT; Ellis MJ; Stopeck A; Reuben JM; Doyle GV; Matera J; Allard WJ; Miller MC; Fritsche HA; Hortobagyi GN; Terstappen LW
    J Clin Oncol; 2005 Mar; 23(7):1420-30. PubMed ID: 15735118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 15 and Eotaxin correlate with the outcome of breast cancer patients vice versa independent of CTC status.
    Vilsmaier T; Heidegger HH; Schröder L; Trapp E; Zehni AZ; Rack B; Janni W; Mahner S; Weissenbacher T; Jeschke U; Mumm JN;
    Arch Gynecol Obstet; 2021 Jan; 303(1):217-230. PubMed ID: 32929618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
    Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform.
    Yap YS; Leong MC; Chua YW; Loh KWJ; Lee GE; Lim EH; Dent R; Ng RCH; Lim JH; Singh G; Tan A; Guan G; Wu A; Lee YF; Bhagat AAS; Lim DW
    PLoS One; 2019; 14(9):e0221305. PubMed ID: 31553731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
    Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
    Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.